Bicara Therapeutics Inc. (BCAX)

NGM – Цена в реальном времени. Валюта: USD

26.87

+0.53 (2.01%)

При закрытии: Jun 26, 2026, 4:00 PM EDT

26.87

-0.00 (-0.00%)

После закрытия: Jun 26, 2026, 4:35 PM EDT

Обзор
Новости
График
Финансы
Дивиденды
Прогноз
Владельцы
Профиль

Bicara Therapeutics Inc. (BCAX)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Bicara Therapeutics Inc. (BCAX)

What Does the Bicara Therapeutics CEO's Sale of 15,000 Shares Mean for Investors?

Bicara Therapeutics Inc. (BCAX) Discusses New Clinical Data on Investigational Therapy for HPV Negative Head and Neck Cancer at ASCO Transcript

Bicara Therapeutics ASCO Data Bolster Ficerafusp Alfa in Head and Neck Cancer

Ficerafusp Alfa Plus Pembrolizumab Demonstrated Differentiated Three-Year Overall Survival and Deep Responses Driven by TGF-β Inhibition in 1L R/M HPV-Negative HNSCC

Bicara Therapeutics Touts Cancer Drug Progress Ahead of 2026 Pivotal Data

Bicara Therapeutics Inc. (BCAX) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Видео

No Data

Пресс-релизы

Ficerafusp Alfa Plus Pembrolizumab Demonstrated Differentiated Three-Year Overall Survival and Deep Responses Driven by TGF-β Inhibition in 1L R/M HPV-Negative HNSCC

Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Bicara Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Search stocks

Bicara Therapeutics Inc. (BCAX)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Bicara Therapeutics Inc. (BCAX)

What Does the Bicara Therapeutics CEO's Sale of 15,000 Shares Mean for Investors?

Bicara Therapeutics Inc. (BCAX) Discusses New Clinical Data on Investigational Therapy for HPV Negative Head and Neck Cancer at ASCO Transcript

Bicara Therapeutics ASCO Data Bolster Ficerafusp Alfa in Head and Neck Cancer

Ficerafusp Alfa Plus Pembrolizumab Demonstrated Differentiated Three-Year Overall Survival and Deep Responses Driven by TGF-β Inhibition in 1L R/M HPV-Negative HNSCC

Bicara Therapeutics Touts Cancer Drug Progress Ahead of 2026 Pivotal Data

Bicara Therapeutics Inc. (BCAX) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Видео

No Data

Пресс-релизы

Ficerafusp Alfa Plus Pembrolizumab Demonstrated Differentiated Three-Year Overall Survival and Deep Responses Driven by TGF-β Inhibition in 1L R/M HPV-Negative HNSCC

Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Bicara Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)